Environment and Pharmaceuticals - Janusinfo

Environment and Pharmaceuticals

Here you can find information about the environmental impact
of pharmaceuticals. You can search for the product name, the 
substance name or to get an overview, search for ATC Code
(ATC group). Unless otherwise stated, the environmental
impact means impact of pharmaceuticals when used.

Information about the classification
The first search view presents information about the classification of the environmental hazard and the environmental risk. The document text for each drug in the database may indicate if T refers to acute or chronic toxicity. The environmental hazard is classified from 0-9, where a high number indicates high properties for making an environmental impact. The classification of the risk is usually based on theoretical calculations of the risk. For more information see the menu to the right, Classification.

For some substances there is also a risk assessment made on the basis of concentrations measured in the environment in Sweden and efficacy studies with high quality. These assessments are presented in the documents for the substances and are made by independent ecotoxicological expertise. Continuous work is underway to provide more substance documents with this type of environmental information and also present comparisons of environmental risk between substances intended for the same indication. (The document text is reached by clicking on the blue-colored document.) Based on this type of risk assessment, a table of environmentally hazardous drugs has been developed within the framework of Stockholm County Council's environmental program 2017-2021.


2018-08-14 Environmentally relevant exposure to an antidepressant alters courtship behaviours in a songbird

2018-06-05 EU:s Watch list
Commission implementing decision (EU) 2018/840 of 5 June 2018

2018-05-17 Joint Statement | Europe must align policies to tackle Pharmaceuticals in the Environment and Antimicrobial Resistance
European public health alliance (epha)

2018-04-12 Industry need to accept responsibility for their pharmaceutical pollution
Health Care Without Harm

2018-04-10 Joint Declaration on Pharmaceuticals in the Environment
European Federation of Pharmaceutical Industries and Associations (EFPIA)

2018-03-06 Declaration of the Ministers of the Environment of the Baltic Coastal Countries and the EU Environment Commissioner, HELCOM Brussels Declaration 2018

2018-02-27 Antimicrobial resistance in zoonotic bacteria still high in humans, animals and food, say ECDC and EFSA
European Food Safety Authority

2018-02-07 Threats to global antimicrobial resistance control Centrally approved and unapproved antibiotic formulations sold in India
British Journal of Clinical Pharmacology

2018-01-22 Tracking progress to address AMR
AMR Industry Alliance

2017-12-21 ECOdrug: a database connecting drugs and conservation of their targets across species
Nucleic Acids Res

2017-12-05 From antimicrobial resistance to off-grid solar: Frontiers 2017 explores the newest environmental issues facing the planet

2017-12-05 Antimicrobial resistance from environmental pollution among biggest emerging health threats, says UN Environment

2017-12-05 Careless disposal of antibiotics could produce ‘ferocious superbugs,’ UN environment experts warn

2017-11-13 Antibiotic resistance is ‘crisis we cannot ignore,’ UN warns, calling for responsible use of these medicines

2017-06-12 Behov av avancerad rening vid avloppsreningsverk. Summary in English.

2016-06-09 Dokumentation from the conference Water and Pharmaceuticals -- insights and perspectives for health and environment 12-13 April, Uppsala, Sweden.

2016-05-11 Rening från läkemedelsrester och andra mikroföroreningar. En kunskapssammanställning. Rapport 2016-04. Summary in English.
Svenskt Vatten

2016-04-12 New recommendations to reduce pharmaceuticals in water
SIWI - the Stockholm International Water Institute

2016-02-02 Drugs past their expiration date

2016-01-12 Recommendations for improving environmental risk assessment of pharmaceuticals
MistraPharmas Policy Brief